Peregrine Pharmaceuticals to Present at Credit Suisse 2013 Healthcare Conference
TUSTIN, CA -- (Marketwired) -- 11/05/13 -- Peregrine
Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company
developing first-in-class monoclonal antibodies focused on the
treatment and diagnosis of cancer, today announced that Steven W.
King, president and chief executive officer, will present a company
update at the Credit Suisse 2013 Healthcare Conference on Tuesday,
November 12, 2013 at 1:00 PM Mountain Time (3:00 PM Eastern Time) at
The Phoenician Hotel, Scottsdale, Arizona.
Peregrine's presentation will be webcast live and available for
replay for 30 days at: http://ir.peregrineinc.com/events.cfm
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a
portfolio of innovative monoclonal antibodies in clinical trials
focused on the treatment and diagnosis of cancer. The company is
pursuing multiple clinical programs in cancer with its lead
immunotherapy candidate bavituximab and novel brain cancer agent
Cotara(R). Peregrine also has in-house cGMP manufacturing
capabilities through its wholly-owned subsidiary Avid Bioservices,
Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. Additional information about Peregrine can be found at
Christopher Keenan or Jay Carlson
Press spacebar to pause and continue. Press esc to stop.